The most successful client companies were AstraZeneca, with 5 Gold awards, and UCB who won 4 Golds plus Best in Show. Other ...

It’s time to shine a light on the next wave of drug discovery.

That’s why we are excited to present the 3rd Gene Therapy Potency Assay Summit, taking place in Boston from May 28-29, 2025.

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

Taiho is parting with $400 million upfront for Araris, a spin-off from the Paul-Scherrer-Institute in Zurich, Switzerland, ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

As Global SME of Life Science and Pharma at Tive, Alex Guillen leads sales and business development within the company's rapid-growth life sciences division. Previously, Guillen served as a Board ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Measles cases in the European region doubled to 127,350 in 2024, reaching the highest level in nearly three decades and ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Nevertheless, the rise in the Statutory Scheme rate to almost a third of pharma company revenue – which brings the average ...